<DOC>
	<DOCNO>NCT01974856</DOCNO>
	<brief_summary>The primary objective study assess extent Prosigna™ Breast Cancer Prognostic Gene Signature Assay affect medical oncologist 's treatment recommendation regard adjuvant chemotherapy actual treatment receive patient early-stage breast cancer .</brief_summary>
	<brief_title>A Prospective Observational Study Clinical Outcomes NanoString® Technologies Prosigna™ Gene Signature Assay</brief_title>
	<detailed_description>Changes treatment recommendation include ( 1 ) hormonal therapy alone , ( 2 ) hormonal therapy plus chemotherapy , ( 3 ) change type chemotherapy chemotherapy recommend test .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Resected nodenegative , estrogenreceptorpositive , HER2negative early stage invasive breast cancer ( T1T2 , N0 , pN0 ( i+ ) , pN0 ( mol+ ) , M0 ) Estrogen receptor status evaluate Immunohistochemistry ( IHC ) 1 % stained tumor cell consider positive . HER2 status evaluate IHC ( 0 1+ , 2+ consider negative ) insitu fluorescence hybridization . Postmenopausal woman define : Natural Amenorrhea &gt; 12 month , regardless age Bilateral oophorectomy , regardless age ( oophorectomy must carry least 4 week enter study ) Radiological castration amenorrhea &gt; 3 month , regardless age Hysterectomy postmenopausal blood level Able give consent Eligible treatment breast cancer adjuvant chemotherapy ECOG performance status 0 1 Tumor size T3T4 Noninvasive breast cancer ( e.g. , Paget 's disease , DCIS ) Tumors node N0 , pN0 ( i+ ) , pN0 ( mol+ ) Tumors estrogenreceptor negative HER2 positive Have metastatic disease Unable give inform consent Unable complete patient report outcome survey Have contraindication adjuvant chemotherapy Age , performance status , significant comorbidities ECOG performance status &gt; 1</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>